Basal markers and prognosis in luminal breast cancer

Engstrøm, Monica Jernberg; Valla, Marit; Bofin, Anna M.

doi:10.1007/s10549-017-4182-z

Cited by 8 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[40][41][42] We regarded SI ≥ 2 as positive, similar to previous studies of other markers. 25,30,40,43 In addition, we observed nuclear staining in a large proportion of cases, and the proportion of stained nuclei, irrespective of staining intensity was recorded. Not including staining intensity in the assessment of nuclear markers is routine both for hormone receptors and Ki67 in breast cancer.…”

Section: Discussionmentioning

confidence: 64%

Characterization of FGD5 Expression in Primary Breast Cancers and Lymph Node Metastases

Valla

Mjønes

Engstrøm

et al. 2018

J Histochem Cytochem.

Self Cite

View full text Add to dashboard Cite

Faciogenital dysplasia 5 ( FGD5) amplification drives tumor cell proliferation, and is present in 9.5% of breast cancers. We describe FGD5 expression, assess associations between FGD5 amplification and FGD5 expression, and assess FGD5 expression in relation to proliferation and prognosis. FGD5 immunohistochemistry was done on primary tumors ( n=829) and lymph node metastases ( n=231) from a cohort of Norwegian patients. We explored associations between FGD5 amplification, FGD5 expression, and proliferation, and analyzed the prognostic value of FGD5 expression by estimating cumulative risks of death and hazard ratios (HRs). We identified nuclear and cytoplasmic expression in 64% and 73% of primary tumors, respectively, and found an association between gene amplification and nuclear expression ( p=0.02). The proportion of cases with FGD5 expression was higher in lymph node metastases, compared with primary tumors ( p=0.004 for nuclear and p=0.001 for cytoplasmic staining). Neither proliferation nor prognosis was associated with FGD5 expression (age-adjusted HR 1.12 [95% confidence interval = 0.89-1.41] for nuclear expression; and 0.88 [95% CI = 0.70-1.12] for cytoplasmic expression). FGD5 is expressed in a high proportion of breast cancers and lymph node metastases. There was a correlation between FGD5 amplification and nuclear expression, but no association between FGD5 expression and proliferation or prognosis.

show abstract

Section: Discussionmentioning

confidence: 64%

Characterization of FGD5 Expression in Primary Breast Cancers and Lymph Node Metastases

Valla

Mjønes

Engstrøm

et al. 2018

J Histochem Cytochem.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Regarding the IHC expression of basal CKs, in our study was observed higher percentage of CK5-positive cases than CK14-positive cases (93.1 % versus 44.8 % respectively) regardless of the histological subtype, and the immunoreaction was observed mainly in neoplastic LE cells. In HBC, the CK5 was also more expressed than CK14, although the difference was lower than in CMCs (24.6 % versus 23.3 % respectively) [ 39 ]. Focusing on the proliferating ME cells, mean complex and mixed CMCs, CK5-positive expression was higher (25.9 and 10 %) than the CK14-positive expression (7.4 and 10 %), respectively.…”

Section: Discussionmentioning

confidence: 99%

Vitamin D receptor (VDR) expression in different molecular subtypes of canine mammary carcinoma

et al. 2021

View full text Add to dashboard Cite

Background The molecular-based classification of canine mammary carcinomas (CMCs) has been the focus of much current research. Both in canines and humans, the triple-negative (TN) molecular subtype of mammary cancer is defined by a lack of expression of progesterone receptor (PR), oestrogen receptor (ER) and HER2. It has a poor prognosis; no effective targeted therapy is available. Vitamin D displays anticarcinogenic properties, and the expression of its receptor (VDR) has been found in different molecular subtypes, being about 30–40 % of TN breast cancer (TNBC) positive to it. We assessed the VDR expression in the different molecular subtypes of 58 CMCs from 45 female dogs using an immunohistochemical panel for the molecular classification of included: PR, ER, HER2, cytokeratin (CK) 5, CK14, and Ki67. In addition, we studied the relationship among the molecular subtypes of CMCs and clinicopathologic parameters. Results Investigation showed VDR positivity in 45.0 % of the triple-negative CMCs (TNCMCs), 27.3 % of luminal B and 19.0 % of luminal A. Luminal A was the most molecular subtype represented of the total tumours (36.2 %), followed of TNCMCs (34.5 %), luminal B (20.7 %) and HER2-overexpression (10.3 %). Both HER2-overexpression and TNCMC subtypes were positively related to lymphatic invasion (P = 0.028), simple histologic subtype (P = 0.007), a higher histological grade (P = 0.045) and a trend to higher proliferation index (P = 0.09). Conclusions The highest VDR expression was observed in TNCMC, being almost half of them (45 %) positive to this receptor. VDR expression was absent in HER2-overexpression tumours and low in luminal A and B molecular subtypes.

show abstract

“…Immunohistochemical staining results for CK5/6, CK14, and EGFR were considered positive when > 1% tumor cells were stained. 23,31 The molecular subtypes of TNBCs were defined according to the immunohistochemical results as follows: (1) LAR, AR-positive; (2) BL, CK5/6-positive and/or CK14positive and/or EGFR-positive; (3) UN, tumors with none of the above features. 23,32 The density of CD3 + and CD8 + T-cell infiltration were evaluated in tumor and stroma region with the highest infiltration.…”

Section: B7-h3 and B7-h4 Mrna And Protein Expression In Tnbcmentioning

confidence: 99%

Comparison of the Clinicopathologic Features and T-Cell Infiltration of B7-H3 and B7-H4 Expression in Triple-negative Breast Cancer Subtypes

Kim¹,

Park

Cho

et al. 2021

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

Previously we revealed an upregulated expression of B7-H3 and B7-H4 mRNA and protein in breast cancer, including triple-negative breast cancer (TNBC). However, little is known regarding the clinical impact and value of B7-H3 and B7-H4 in TNBC subtypes. Thus, this study evaluated the clinicopathologic effects of B7-H3 and B7-H4 mRNA and protein expression according to the TNBC subtypes. RNAscope in situ hybridization and immunohistochemistry of B7-H3 and B7-H4 was done for 186 TNBC samples using tissue microarray. Immunohistochemistry was also performed for TNBC molecular subtype-surrogate markers, CD3, and CD8. TNBCs were classified into basal-like (BL) (64.5%), luminal androgen receptor (10.8%), and unclassifiable (24.7%) subtypes. Tumor B7-H4 mRNA expression was associated with younger age at the initial diagnosis and with molecular TNBC subtypes. Expression of B7-H3 mRNA and protein in the tumor cells was negatively correlated with CD3 + and CD8 + T-cell infiltration density in the tumor and/or stromal region of TNBCs and their subtypes. High stromal B7-H3 mRNA expression was associated with poor disease-free and overall survival in the TNBCs and with overall survival in the unclassifiable subtype. Stromal B7-H3 mRNA expression was independently associated with overall survival and disease-free survival in the TNBCs and BL subtype, respectively. Our results indicate the importance of the stromal expression of B7-H3 mRNA as a prognostic factor in the TNBCs and BL subtype. The inverse relationship between B7-H3 expression and CD3 + and CD8 + T-lymphocyte infiltration represents a promising target for immunotherapy for the TNBCs, especially the BL subtype.

show abstract

Basal markers and prognosis in luminal breast cancer

Cited by 8 publications

References 32 publications

Characterization of FGD5 Expression in Primary Breast Cancers and Lymph Node Metastases

Characterization of FGD5 Expression in Primary Breast Cancers and Lymph Node Metastases

Vitamin D receptor (VDR) expression in different molecular subtypes of canine mammary carcinoma

Comparison of the Clinicopathologic Features and T-Cell Infiltration of B7-H3 and B7-H4 Expression in Triple-negative Breast Cancer Subtypes

Contact Info

Product

Resources

About